Catalent is the global leader in enabling pharmaceutical, biotechnology, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients globally. With broad scale and deep expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Helping to accelerate over 1,000 partner programs, and launch over 150 new products every year, Catalent’s flexible manufacturing platforms, at over 50 global sites, supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including over 2,500 scientists.
In both the U.S. and Europe, Catalent has recently announced extensive investments to enhance and expand its full range of development and commercial drug substance and drug product capabilities across biotherapeutics, vaccines, and plasmids, as well as cell and gene therapies.
Catalent offers integrated development and product supply solutions that can be combined or tailored, to enable customers to progress drugs, biologics, and consumer health products from laboratory to market, faster. Post-launch, Catalent provides comprehensive, integrated product supply, from sourcing bulk API through to manufacturing and packaging, release testing, and distribution. These flexible, scalable, and creative solutions meet the unique needs of both large and emerging biopharma and consumer health companies.
More products. Better treatments. Reliably supplied.TM
Posted Date: 12/1/2021
This record has been viewed 5140 times.